Autolus Therapeutics Plc (AUTL)

NASDAQ:AUTL

AUTL

Autolus Therapeutics

RESEARCH TOOLSreports

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

925 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AUTL Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Autolus

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AUTL Stock 12 Month Forecast

Average Price Target

$8.40

▲(504.32% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Autolus Therapeutics in the last 3 months. The average price target is $8.40 with a high forecast of $10.00 and a low forecast of $5.00. The average price target represents a 504.32% change from the last price of $1.39.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,2.043076923076923,2.706153846153846,3.3692307692307693,4.032307692307692,4.695384615384615,5.358461538461539,6.021538461538461,6.684615384615385,7.347692307692308,8.010769230769231,8.673846153846153,9.336923076923078,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,1.92,2.46,3,3.54,4.08,4.62,5.16,5.7,6.24,6.78,7.32,7.86,{"y":8.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,1.6584615384615384,1.936923076923077,2.2153846153846155,2.493846153846154,2.7723076923076926,3.0507692307692307,3.329230769230769,3.6076923076923078,3.8861538461538463,4.164615384615384,4.443076923076923,4.7215384615384615,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.41,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 46, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 56, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$10.00

Average Price Target$8.40

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Salim Syed

Mizuho Securities

$12→$10

Buy

619.42%

Upside

Assigned

03/30/26

Autolus Therapeutics price target lowered to $10 from $12 at MizuhoAutolus Therapeutics price target lowered to $10 from $12 at Mizuho

Gil Blum

Needham

$10

Buy

619.42%

Upside

Reiterated

03/27/26

Analysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (NASDAQ: KPRX), Zentalis Pharmaceuticals (NASDAQ: ZNTL) and Autolus Therapeutics (NASDAQ: AUTL)

Matt Phipps

William Blair

―

Buy

―

Reiterated

03/27/26

Autolus: Transition-Year Execution and Aucatzyl Expansion Underscore Buy-Rated Long-Term Upside

Emily Bodnar

H.C. Wainwright

Buy

547.48%

Upside

Initiated

02/17/26

Analysts Are Bullish on Top Healthcare Stocks: Citius Oncology (CTOR), Autolus Therapeutics (AUTL)

Yanan Zhu

Wells Fargo

Buy

259.71%

Upside

Reiterated

01/14/26

Wells Fargo Keeps Their Buy Rating on Autolus Therapeutics (AUTL)

Asthika Goonewardene

Truist Financial

$10→$8

Buy

475.54%

Upside

Reiterated

01/13/26

Truist Financial Sticks to Its Buy Rating for Autolus Therapeutics (AUTL)

Rajan Sharma

Goldman Sachs

$5.6→$5.7

Buy

310.07%

Upside

Reiterated

11/13/25

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (NASDAQ: PDSB) and Autolus Therapeutics (NASDAQ: AUTL)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Salim Syed

Mizuho Securities

$12→$10

Buy

619.42%

Upside

Assigned

03/30/26

Autolus Therapeutics price target lowered to $10 from $12 at MizuhoAutolus Therapeutics price target lowered to $10 from $12 at Mizuho

Gil Blum

Needham

$10

Buy

619.42%

Upside

Reiterated

03/27/26

Analysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (NASDAQ: KPRX), Zentalis Pharmaceuticals (NASDAQ: ZNTL) and Autolus Therapeutics (NASDAQ: AUTL)

Matt Phipps

William Blair

―

Buy

―

Reiterated

03/27/26

Autolus: Transition-Year Execution and Aucatzyl Expansion Underscore Buy-Rated Long-Term Upside

Emily Bodnar

H.C. Wainwright

Buy

547.48%

Upside

Initiated

02/17/26

Analysts Are Bullish on Top Healthcare Stocks: Citius Oncology (CTOR), Autolus Therapeutics (AUTL)

Yanan Zhu

Wells Fargo

Buy

259.71%

Upside

Reiterated

01/14/26

Wells Fargo Keeps Their Buy Rating on Autolus Therapeutics (AUTL)

Asthika Goonewardene

Truist Financial

$10→$8

Buy

475.54%

Upside

Reiterated

01/13/26

Truist Financial Sticks to Its Buy Rating for Autolus Therapeutics (AUTL)

Rajan Sharma

Goldman Sachs

$5.6→$5.7

Buy

310.07%

Upside

Reiterated

11/13/25

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (NASDAQ: PDSB) and Autolus Therapeutics (NASDAQ: AUTL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Autolus Therapeutics

3 Months

xxx

Success Rate

9/22 ratings generated profit

Average Return

-2.41%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.91% of your transactions generating a profit, with an average return of -2.41% per trade.

1 Year

Asthika GoonewardeneTruist Financial

Success Rate

8/22 ratings generated profit

Average Return

-8.37%

reiterated a buy rating 3 months ago

Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -8.37% per trade.

2 Years

xxx

Success Rate

7/22 ratings generated profit

Average Return

-27.34%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 31.82% of your transactions generating a profit, with an average return of -27.34% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AUTL Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AUTL has received 5 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. AUTL average Analyst price target in the past 3 months is 8.40.

Each month's total comprises the sum of three months' worth of ratings.

AUTL Financial Forecast

AUTL Earnings Forecast

The previous quarter’s earnings for AUTL were -$0.34.

AUTL Sales Forecast

The previous quarter’s earnings for AUTL were $24.25M.

AUTL Stock Forecast FAQ

What is AUTL’s average 12-month price target, according to analysts?

Based on analyst ratings, Autolus Therapeutics Plc’s 12-month average price target is 8.40.

What is AUTL’s upside potential, based on the analysts’ average price target?

Autolus Therapeutics Plc has 504.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AUTL a Buy, Sell or Hold?

Autolus Therapeutics Plc has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Autolus Therapeutics Plc’s price target?

The average price target for Autolus Therapeutics Plc is 8.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $5.00. The average price target represents 504.32% Increase from the current price of $1.39.

What do analysts say about Autolus Therapeutics Plc?

Autolus Therapeutics Plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of AUTL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

AUTL Analyst Ratings

AUTL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Autolus Therapeutics

AUTL Analyst Recommendation Trends

AUTL Financial Forecast

AUTL Earnings Forecast

AUTL Sales Forecast

AUTL Stock Forecast FAQ

Detailed List of Analyst Forecasts